BCH (BCH) Stock Price & Analysis
BCH (BCH) rose 6.05% to USD 38.54 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
BCH last closed at USD 36.34; the session ranged USD 36.75–38.57 on volume of 766,442 shares. Market capitalization is $19.47B, with a 52-week range of USD 27.08–46.77 (NYQ). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 38.54 |
|---|---|
| Change | ▲ 6.05% (up) |
| Previous Close | USD 36.34 |
| Open | USD 37.04 |
| Day Range | USD 36.75 – 38.57 |
| 52-Week Range | USD 27.08 – 46.77 |
| Volume | 766,442 shares |
| Market Cap | $19.47B |
| Exchange | NYQ |
Technical Analysis (BCH)
Nexqual's technical model rates BCH "BUY" based on 4 bullish and 2 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 55.64 (neutral) |
| vs SMA50 | Above (USD 37.56) |
| MACD | -0.03 (negative) |
Analyst Ratings (BCH)
Wall Street analysts rate BCH "Hold" based on 13 analysts, with a mean price target of USD 37.68 (range USD 21–47), per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 13 |
| Mean Target | USD 37.68 |
| High Target | USD 47 |
| Low Target | USD 21 |
| Buy / Hold / Sell | 3 / 8 / 2 |
Earnings (BCH)
| Next Earnings Date | 2026-07-31 |
|---|---|
| EPS Estimate | USD 0.68 |
| Revenue Estimate | $829.91B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.59 vs est 0.6 ▼ miss |
| 2025-12-31 | USD 0.61 vs est 0.66 ▼ miss |
| 2025-09-30 | USD 0.62 vs est 0.64 ▼ miss |
| 2025-06-30 | USD 0.62 vs est 0.65 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (BCH)
| Revenue Growth (YoY) | -7.90% |
|---|---|
| Gross Margin | +0.00% |
| Operating Margin | +0.00% |
| Profit Margin | +43.71% |
| ROE | +20.85% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (BCH)
Nexqual rates BCH's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Weak — Revenue -1% YoY (annual), declining |
|---|---|
| Profitability | Weak — Gross margin 0%, operating 0% |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Strong — ROE 21%, ROA 2.1% |
Ownership (BCH)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +2.28% |
| Shares Outstanding | 505.09M |
| Float | 189.09M |
| Short % of Float | +0.38% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (BCH)
BCH is led by Eduardo Ebensperger Orrego (age 60), Chief Executive Officer, per Nexqual as of June 10, 2026 at 00:50 UTC.
| Chief Executive Officer | Eduardo Ebensperger Orrego (age 60) |
|---|---|
| Director | Hernan Buchi Buc (age 76) |
| Chief Financial Officer | Rolando Arias Sanchez (age 60) |
| General Counsel & Secretary of the Board of Directors | Alfredo Villegas Montes (age 54) |
Major Backers & Investors (BCH)
Notable institutional backers of BCH include Renaissance Technologies, American Century Companies Inc, TT International Asset Management LTD, according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Renaissance Technologies | 0.24% |
| American Century Companies Inc | 0.16% |
| TT International Asset Management LTD | 0.14% |
| UBS Group AG | 0.11% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Dimensional Fund Advisors | 0.2% |
| BlackRock | 0.17% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BSAC | Banco Santander - Chile | USD 31.4 | ▲ 4.6% |
| CIB | Grupo Cibest S.A. | USD 74.9 | ▲ 5.67% |
| SHG | Shinhan Financial Group Co Ltd | USD 65.99 | ▼ 1.76% |
| BAP | Credicorp Ltd. | USD 349.61 | ▲ 8.41% |
| BSBR | Banco Santander Brasil SA | USD 5.28 | ▲ 0.76% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.